{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:52:53Z","timestamp":1763967173139,"version":"build-2065373602"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The New York Center for Travel and Tropical Medicine","award":["D-129-18-00"],"award-info":[{"award-number":["D-129-18-00"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Highlight<\/jats:title>\n               <jats:p>What can be concluded from a clinical trial that spanned 5\u00a0years yet failed to achieve target enrollment, generated flat results that contradict the existing body of knowledge and has a primary efficacy endpoint confounded by a treatment-by-COVID interaction? Could it be a false negative finding?<\/jats:p>","DOI":"10.1093\/jtm\/taaf076","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T11:42:31Z","timestamp":1753530151000},"source":"Crossref","is-referenced-by-count":1,"title":["Revisiting the efficacy of bismuth subsalicylate for the prevention of traveller\u2019s diarrhoea"],"prefix":"10.1093","volume":"32","author":[{"given":"Roger D","family":"Gibb","sequence":"first","affiliation":[{"name":"Healthcare Biostatistics, The Procter and Gamble Company , Mason, OH 45040 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M","family":"Brum","sequence":"additional","affiliation":[{"name":"Healthcare Clinical, The Procter and Gamble Company , Mason, OH 45040 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle J","family":"Sloan","sequence":"additional","affiliation":[{"name":"Healthcare R&D, The Procter and Gamble Company , Mason, OH 45040 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam M","family":"Pitz","sequence":"additional","affiliation":[{"name":"Healthcare R&D, The Procter and Gamble Company , Mason, OH 45040 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin T","family":"Circello","sequence":"additional","affiliation":[{"name":"Healthcare R&D, The Procter and Gamble Company , Mason, OH 45040 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowan A","family":"Grayling","sequence":"additional","affiliation":[{"name":"Healthcare R&D, The Procter and Gamble Company , Mason, OH 45040 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"2025100302021544900_ref1","doi-asserted-by":"crossref","first-page":"taaf047","DOI":"10.1093\/jtm\/taaf047","article-title":"Efficacy of bismuth subsalicylate on the prevention of travelers\u2019 diarrhea, 2018\u20132023","author":"Angelo","year":"2025","journal-title":"J Travel Med"},{"key":"2025100302021544900_ref2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.1980.03300290019013","article-title":"Prevention of traveler's diarrhea (emporiatric enteritis): prophylactic administration of subsalicylate bismuth","volume":"243","author":"DuPont","year":"1980","journal-title":"JAMA"},{"key":"2025100302021544900_ref3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/AAC.29.4.625","article-title":"Prevention of traveler's diarrhea by the tablet form of bismuth subsalicylate","volume":"29","author":"Steffen","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100302021544900_ref4","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.1987.03390100085031","article-title":"Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate","volume":"257","author":"DuPont","year":"1987","journal-title":"JAMA"},{"key":"2025100302021544900_ref5","doi-asserted-by":"crossref","first-page":"taae008","DOI":"10.1093\/jtm\/taae008","article-title":"Incidence and risk factors for travellers\u2019 diarrhoea among short-term international adult travellers from high-income countries: a systematic review with meta-analysis of cohort studies","volume":"32","author":"Carroll","year":"2025","journal-title":"J Travel Med"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taaf076\/63854336\/taaf076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/32\/6\/taaf076\/63854336\/taaf076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/32\/6\/taaf076\/63854336\/taaf076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:02:22Z","timestamp":1759471342000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taaf076\/8213841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":5,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,7,26]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taaf076","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"type":"print","value":"1195-1982"},{"type":"electronic","value":"1708-8305"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,26]]},"article-number":"taaf076"}}